Azar Says J&J (JNJ) Vaccine Trial Setback Shouldn't Alter Timeline - Bloomberg
Tweet
Share
E-mail
Get Alerts JNJ Hot Sheet
Price: $275.21 --0%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2%
Revenue Growth %: +5.5%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2%
Revenue Growth %: +5.5%
Join SI Premium – FREE
Azar Says J&J (NYSE: JNJ) Vaccine Trial Setback Shouldn't Alter Timeline - Bloomberg
- Health Secretary Says Two Vaccine Trails Almost Enrolled
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
- Scholar Rock gets FDA fast track for apitegromab in rare muscle disease
- Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
Create E-mail Alert Related Categories
FDA, PoliticsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
